Anabolic & growth

IGF-1 LR3

Also known as: Long R3 IGF-1

A modified, longer-acting version of IGF-1 — the downstream effector of growth hormone.

growthrecoveryanabolic
Half-life
~20–30 hours
Route
Subcutaneous injection
Shelf life (powder)
24+ months refrigerated
Shelf life (mixed)
~2–3 weeks refrigerated
Storage
Fridge. Light- and pH-sensitive.

Read this first

This is plain-language harm-reduction information, not medical advice. Peptides discussed here are research compounds; most are not approved for human use. People will use them either way — we would rather they have the facts.

What it is

IGF-1 (insulin-like growth factor 1) is the hormone produced by the liver in response to growth hormone — it is responsible for most of GH's anabolic effects. IGF-1 LR3 is a synthetic version modified to last around three days in the body instead of minutes.

It is one of the most aggressive anabolic peptides in common use. Side-effect and safety profile reflects that.

History

Originally developed for laboratory cell-culture work in the 1990s. The "LR3" stands for "Long R3" — three modifications that extend its half-life and reduce binding to IGFBPs.

How it works

Binds the IGF-1 receptor and triggers anabolic signalling (cell growth, protein synthesis, glucose uptake into muscle).

Dosage

  • 20–80 mcg daily.
  • Cycle 4–6 weeks on, then break (receptors downregulate).

How it is taken

  • Subcutaneous belly injection. Some users inject bilaterally near worked muscles, though systemic effect dominates.

How to reconstitute

  • 1 mg vial with 2 ml BAC water = 500 mcg/ml. 40 mcg = 8 units on a 1 ml insulin syringe.
  • Bacteriostatic water can degrade IGF-1 LR3 — some users prefer 0.6% acetic acid solution. Trade-off: stability vs comfort.

How it should arrive

White powder, sealed vial. Often shipped on cold pack.

How it should look once reconstituted

Clear colourless solution.

What to expect, and when

  • Pump and muscle fullness: within days.
  • Body composition changes: 2–4 weeks.
  • Diminishing returns and receptor downregulation: 4–6 weeks.

Side effects

  • Hypoglycaemia — IGF-1 LR3 increases glucose uptake into muscle. Eating regularly after dosing is critical.
  • Increased hunger.
  • Possible enlargement of internal organs at high doses over time.
  • Lethargy in some users.

Risks

  • Strong theoretical cancer-promotion concern — IGF-1 is a known cell-proliferation signal.
  • Hypoglycaemia can become severe at higher doses.
  • WADA prohibited.

Potential gains

  • Rapid increases in muscle fullness and pump.
  • Notable lean mass gains over 4-week cycles.
  • Some users report joint discomfort improvement.

Other useful information

One of the most aggressive peptides on the market. The cancer-promotion concern is the most legitimate red flag of any peptide in this catalogue. Worth thinking hard about whether the gains justify the unknown.

Looking for a goal-based recommendation?

Try the Find your goal tool — answer five short questions and get peptides matched to what you actually want.